Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Deferred Revenue for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 77.61% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 77.61% decrease, with the full-year FY2025 number at $2.6 million, down 77.61% from a year prior.
  • Current Deferred Revenue was $2.6 million for Q4 2025 at TScan Therapeutics, down from $5.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $19.2 million in Q2 2023 to a low of $2.6 million in Q4 2025.
  • A 5-year average of $9.8 million and a median of $10.4 million in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 161.67% in 2023, then tumbled 77.61% in 2025.
  • TScan Therapeutics' Current Deferred Revenue stood at $11.4 million in 2021, then plummeted by 66.05% to $3.9 million in 2022, then skyrocketed by 161.67% to $10.1 million in 2023, then grew by 15.4% to $11.7 million in 2024, then crashed by 77.61% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Current Deferred Revenue are $2.6 million (Q4 2025), $5.2 million (Q3 2025), and $7.7 million (Q2 2025).